Genmab (GMAB) said Sunday that results from a phase 1b/2 trial of its experimental epcoritamab treatment in combination with other drugs in patients with relapsed/refractory diffuse large B-cell lymphoma showed an overall response rate of 87%.
The results cover patients who are eligible for autologous stem cell transplantation.
The company said results also showed a complete response rate of 65%, and a partial response rate of 23%.
Safety data from the trial showed a low-grade cytokine release syndrome and no discontinuations due to treatment-emergent adverse events, Genmab said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。